炎症性肠病的外科治疗进展

2016-05-18 北京协和医院基本外科 中国医学论坛报

炎症性肠病(IBD)是一组病因尚不十分清楚的慢性非特异性肠道炎症性疾病,包括溃疡性结肠炎(UC)和克罗恩病(CD)。IBD是北美和欧洲的常见病,但近十余年来,我国IBD发病率亦呈逐步增高的趋势。

炎症性肠病(IBD)是一组病因尚不十分清楚的慢性非特异性肠道炎症性疾病,包括溃疡性结肠炎(UC)和克罗恩病(CD)。IBD是北美和欧洲的常见病,但近十余年来,我国IBD发病率亦呈逐步增高的趋势。
  
IBD虽然属于内科疾病,但由于慢性炎症的反复发作,可能导致肠梗阻、内/外瘘、穿孔或癌变,以及内科治疗无效等原因,约80%的CD患者和25%的UC患者需接受手术治疗。因此,外科手术是IBD不可缺少的治疗手段之一。
  
克罗恩病的外科治疗
  
CD在一定程度上被认为是一种难以治愈的终身性疾病,通常需要胃肠病专家、外科医生及患者共同参与来制定最佳的治疗方案。

美国克利夫兰诊所的法齐奥(Fazio)教授总结CD的三大特征为:①大多数患者在某时需手术治疗;②永远有再次手术的可能;③始发病变的类型不同时,其预后和复发也不同。约80%的患者在病程中需至少接受1次手术治疗。通过外科干预,常可缓解症状、改善病情、提高患者的生活质量,但术后有较高的复发率及再手术率。

手术指征

CD的手术指征包括:患者出现CD并发症和内科治疗无效。

CD并发症包括①肠梗阻:由纤维狭窄所致的肠梗阻视病变部位和范围行肠段切除术或狭窄成形术,炎症性狭窄引起的梗阻如药物治疗无效可考虑手术治疗;②腹腔脓肿:先行经皮脓肿引流和抗感染,必要时再行手术处理病变肠段;③瘘管形成:有症状的单纯性肛瘘以及复杂性肛瘘;非肛周瘘管(包括肠皮瘘和各种内瘘)的处理应由内外科医师密切配合进行个体化处理;④急性穿孔;⑤大出血:内科治疗(包括内镜止血)出血无效而危及生命者,需要急诊手术;⑥癌变。

内科治疗无效①激素等药物治疗难以控制的重症CD;②内科治疗疗效不佳和(或)药物不良反应已严重影响生活质量者,可考虑外科手术。

需接受手术的CD患者往往存在营养不良、合并感染,部分患者长期使用激素,手术风险较大。因此充分的术前准备是必要的,如感染控制、营养支持,除伴有大出血外,一般不宜施行急诊手术。

手术方式

CD的手术方式主要包括:病变肠段切除术、狭窄成形术和肠旁路手术等,需要依据CD病变部位(小肠或结肠)、严重程度、内科治疗情况、患者全身状况及患者意愿,来合理选择。

手术时不应切除所有病变肠管,而是仅处理引起外科症状的部位,采用这种策略可显著降低广泛肠切除导致短肠综合征的风险。

病变小肠肠段切除术是CD手术治疗的传统术式之一。CD有累及全消化系统的特性,且术后复发率高,常需要再次手术,容易导致短肠综合征。切除CD小肠病变时应遵循“节省肠管”的原则,建议根据肉眼下判断的病变范围切除肠管,肠管切除范围限于肉眼病变肠管两侧2cm。

小肠狭窄成形术通过松解和扩大狭窄部位,避免了肠切除,已成为CD患者确定性手术方法。该术式可治疗梗阻性CD,特别是多处较短纤维化狭窄,以及已行广泛多次手术有短肠综合征危险的患者。对于7cm以内的狭窄,可行Heineke-Mikulicz狭窄成形术;7~10cm的狭窄,宜用Finney狭窄成形术。

结肠节段性病变局限的CD患者可行节段结肠切除,有利于保留结肠长度;若CD患者有2段或更多节段的结肠受累,则可行全结肠切除回肠直肠吻合术;对于弥漫性结直肠炎的患者,可考虑行全结直肠切除、回肠造口术。

CD合并肛周病变如有脓肿形成必须先行外科充分引流,并予抗菌药物治疗。无症状的单纯性肛瘘无需处理。有症状的单纯性肛瘘以及复杂性肛瘘应由肛肠外科医师根据病情决定是否需手术以及术式的选择(如单纯性肛瘘瘘管切除术、复杂性肛瘘挂线疗法,甚至肠道转流术或直肠切除术)。

小结

总之,IBD的治疗应以合理、规范、综合和个体化为指导原则,强调多学科协作治疗(MDT)综合诊疗模式。针对不同患者的特定病情,制定基于指南的规范化治疗和专家经验的个体化诊治方案。随着MDT综合诊疗模式、微创治疗模式的规范化和推广,IBD患者能够获得最佳的外科干预时机、更小的手术创伤和更好的术后生活质量。

溃疡性结肠炎的外科治疗

手术指征

尽管大多数UC患者通过内科治疗有效,但仍有约20%~30%患者需要接受手术治疗。一般而言,UC外科手术治疗绝对指征为大出血、穿孔、癌变及高度疑为癌变。相对手术指征为:①积极内科治疗无效的重度UC;②内科疗效不佳和(或)药物不良反应已严重影响生存质量者。

重症UC处理

重症UC病情重、发展快,处理不当会危及生命,在治疗初始即应进行多学科诊疗干预。静脉足量激素治疗3天无效者,应考虑转换治疗,一是转换药物治疗,包括环孢素A、他克莫司和英夫利西单抗(IFX),4~7天后评估无效则手术治疗;二是立即手术治疗。不恰当的拖延手术时机可导致更多的手术并发症风险和增加死亡风险。

术式选择

UC合并癌变、平坦黏膜上的高度异型增生应行全结直肠切除;平坦黏膜上的低度异型增生可行全结直肠切除,或3~6个月后随访,如仍为同样改变亦应行全结直肠切除;隆起型息肉上发现异型增生而不伴有周围平坦黏膜上的异型增生,可行内镜下治疗,如无法行内镜下治疗则应考虑行全结直肠切除。

全结直肠切除加回肠贮袋肛管吻合手术(IPAA)是目前UC的首选手术方式。该术式在切除全部大肠后,用末端回肠构建贮袋与肛管吻合。双吻合技术的普及,使得IPAA手术更加安全有效,并发症发生率为19%~27%,死亡率0.2%~0.4%,术后生活质量接近正常人群。由于手术涉及全结直肠的切除和回肠贮袋制作,一般建议在每年IPAA手术超过10例的中心进行手术。

IPAA手术可以分为一期、二期和三期完成。一期IPAA和二期IPAA手术的区别在于是否同时行近端回肠预防性转流造口。目前,大多数单位(超过90%)行二期IPAA手术,预防性回肠造口可以降低吻合口瘘和盆腔感染风险。下列情况时应选择三期IPAA手术:①急诊重症UC;②术前应用泼尼松用量超过20mg/d,或者术前使用激素时间超过6周;③可疑CD;④重度营养不良;⑤术前12周以内使用过IFX。三期IPAA手术更为安全,即一期行结肠次全切除回肠造口,二期切除直肠并做IPAA及预防性回肠造口,三期关闭回肠造口。

对于具备丰富腹腔镜手术经验的结直肠外科医生而言,腹腔镜全结直肠切除在手术安全性、术后远期控便功能等方面效果与剖腹手术相当。尤其是对于视野不良的盆腔内操作,腹腔镜下良好的视野保证剥离操作的安全,更利于保留植物神经功能。与传统剖腹手术相比,腹腔镜全结直肠切除加IPAA手术不仅具有切口小、出血少、术后住院时间缩短等好处,还降低术后腹腔粘连的风险,减少术后肠粘连等并发症的发生。微创治疗是结直肠手术未来的发展趋势,越来越多地应用于IBD的外科手术治疗。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=90837, encodeId=0eb19083e0c, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 22 22:46:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86728, encodeId=927986e28f2, content=值得好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJPXDw7FHXZf9ounibcIkI3fbic3dlp798gIhH5kDDJeJZ4LANiaujtG5m3tbxhE81eZmsR42I0IFFZw/132, createdBy=e2cc1654754, createdName=Sophia2058, createdTime=Sat May 21 08:19:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547018, encodeId=653c154e018c6, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri May 20 08:13:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86595, encodeId=23f986595ae, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu May 19 08:25:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86547, encodeId=deff8654e12, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu May 19 07:39:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86502, encodeId=42758650257, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 06:45:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-06-22 1dd8c52fm63(暂无匿称)

    好好学习!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=90837, encodeId=0eb19083e0c, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 22 22:46:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86728, encodeId=927986e28f2, content=值得好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJPXDw7FHXZf9ounibcIkI3fbic3dlp798gIhH5kDDJeJZ4LANiaujtG5m3tbxhE81eZmsR42I0IFFZw/132, createdBy=e2cc1654754, createdName=Sophia2058, createdTime=Sat May 21 08:19:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547018, encodeId=653c154e018c6, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri May 20 08:13:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86595, encodeId=23f986595ae, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu May 19 08:25:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86547, encodeId=deff8654e12, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu May 19 07:39:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86502, encodeId=42758650257, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 06:45:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-05-21 Sophia2058

    值得好好学习一下

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=90837, encodeId=0eb19083e0c, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 22 22:46:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86728, encodeId=927986e28f2, content=值得好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJPXDw7FHXZf9ounibcIkI3fbic3dlp798gIhH5kDDJeJZ4LANiaujtG5m3tbxhE81eZmsR42I0IFFZw/132, createdBy=e2cc1654754, createdName=Sophia2058, createdTime=Sat May 21 08:19:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547018, encodeId=653c154e018c6, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri May 20 08:13:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86595, encodeId=23f986595ae, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu May 19 08:25:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86547, encodeId=deff8654e12, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu May 19 07:39:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86502, encodeId=42758650257, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 06:45:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=90837, encodeId=0eb19083e0c, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 22 22:46:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86728, encodeId=927986e28f2, content=值得好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJPXDw7FHXZf9ounibcIkI3fbic3dlp798gIhH5kDDJeJZ4LANiaujtG5m3tbxhE81eZmsR42I0IFFZw/132, createdBy=e2cc1654754, createdName=Sophia2058, createdTime=Sat May 21 08:19:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547018, encodeId=653c154e018c6, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri May 20 08:13:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86595, encodeId=23f986595ae, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu May 19 08:25:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86547, encodeId=deff8654e12, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu May 19 07:39:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86502, encodeId=42758650257, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 06:45:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-05-19 李继凯

    不错的文章

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=90837, encodeId=0eb19083e0c, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 22 22:46:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86728, encodeId=927986e28f2, content=值得好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJPXDw7FHXZf9ounibcIkI3fbic3dlp798gIhH5kDDJeJZ4LANiaujtG5m3tbxhE81eZmsR42I0IFFZw/132, createdBy=e2cc1654754, createdName=Sophia2058, createdTime=Sat May 21 08:19:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547018, encodeId=653c154e018c6, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri May 20 08:13:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86595, encodeId=23f986595ae, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu May 19 08:25:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86547, encodeId=deff8654e12, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu May 19 07:39:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86502, encodeId=42758650257, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 06:45:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-05-19 1dd8c52fm63(暂无匿称)

    了解一下!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=90837, encodeId=0eb19083e0c, content=好好学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 22 22:46:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86728, encodeId=927986e28f2, content=值得好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJPXDw7FHXZf9ounibcIkI3fbic3dlp798gIhH5kDDJeJZ4LANiaujtG5m3tbxhE81eZmsR42I0IFFZw/132, createdBy=e2cc1654754, createdName=Sophia2058, createdTime=Sat May 21 08:19:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547018, encodeId=653c154e018c6, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Fri May 20 08:13:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86595, encodeId=23f986595ae, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu May 19 08:25:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86547, encodeId=deff8654e12, content=了解一下!, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu May 19 07:39:00 CST 2016, time=2016-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86502, encodeId=42758650257, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Thu May 19 06:45:00 CST 2016, time=2016-05-19, status=1, ipAttribution=)]
    2016-05-19 milkshark

    值得学习

    0

相关资讯

Am J Pathol:IBD患者绿茶和膳食铁不宜同时摄入

绿茶因其强大的抗氧化功能而具有很多健康益处,但是一项针对炎症性肠病(inflammatory bowel disease, IBD)模式小鼠的新研究提示着同时摄入绿茶与膳食铁可能实际上降低绿茶的益处。相关研究结果于2016年3月8日在线发表在American Journal of Pathology期刊上。 论文通信作者、美国宾夕法尼亚州立大学营养科学系助理教授Matam Vijay-Kumar

Science:寄生虫或可帮助人类对抗炎症性肠病

寄生虫是一些令人讨厌的小东西,它们会钻入我们体内,偷走我们的营养,吸食我们的血液。然而Science杂志发表的一项最新研究表明,寄生性的肠道蠕虫能对肠道菌组成起到有益影响,帮助人体对抗炎症性肠病。 为了模拟炎症性肠病(Crohn's disease),Deepshika Ramanan及其同事构建了缺乏基因Nod2的小鼠。这些小鼠会出现明显的小肠异常,包括粘液层受损和细胞形态改变。研究人员发现,

Gastroenterology:亚洲早期炎症性肠病流调结果

亚洲炎症性肠病(IBD)的发生率在上升,但是对该地区该疾病的进展认识却很少。始于2011年的关于亚太地区克罗恩病(CD)和溃疡性结肠炎(UC)流行病学研究涉及了中国、香港、印度尼西亚、斯里兰卡、澳门、马来西亚、新加坡、泰国和澳大利亚等区域,研究者目前的研究数据来自这正在进行的研究。研究者纳入了2011-2013年间的413名平均年龄37岁的IBD患者,其中222名UC患者,181名CD患者,10名

Digestion:处于疾病活动期和使用糖皮质激素的炎症性肠病患者更容易发生贫血

贫血是炎症性肠病(IBD)患者最常见的并发症。本研究旨在评估在IBD患者的贫血患病率,并了解其特点。

Pediatrics:无创检查诊断小儿炎症性肠病的指标有哪些?

小儿炎症性肠病(IBD)的临床表现通常不具有特异性,还会误诊为功能性胃肠疾病。研究者检索相关数据库,分析关于儿童慢性胃肠道症状中IBD诊断方式精确性的研究,IBD经过内窥镜检查和组织病理学或临床随访以确定。以探究症状、体征、非侵入性检查等对IBD诊断的精确性。该荟萃分析纳入了19篇研究,涉及2806名患者。研究数据显示,症状如腹痛、腹泻、直肠出血、体重下降等诊断IBD敏感性0.48-0.82,特异